Retatrutide 10mg

The triple agonist. GLP-1, GIP, and glucagon — three pathways, one compound.

$ 190.00

Personalized guidance 1 on 1

Full refund if our licensed clinician determines the treatment isn’t a fit for you

MOA

Overview

Retatrutide is the most advanced metabolic research compound currently in clinical development. A triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, it surpasses the mechanism of both semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) by adding glucagon receptor activation — which directly increases energy expenditure and raises metabolic rate at rest. Phase 2 clinical data has demonstrated up to approximately 24% body weight reduction, approaching bariatric surgery outcomes.

What it does

GLP-1 receptor activation reduces appetite and slows gastric emptying. GIP receptor activation improves insulin secretion and metabolic function. Glucagon receptor activation is the key differentiator — it increases caloric expenditure even at rest by stimulating fat oxidation and thermogenesis through brown adipose tissue, a mechanism not present in prior GLP-1 therapies. The combined effect targets energy intake, energy expenditure, and metabolic efficiency simultaneously.

Research areas

Obesity and significant weight reduction research · Metabolic syndrome · Insulin resistance · Body recomposition · Next-generation GLP-1 comparator research · NASH and hepatic fat reduction

Key facts

Form	Lyophilised powder — requires reconstitution with bacteriostatic water
Storage	Lyophilised: -20°C. Reconstituted: 2–8°C, use within 28 days
Purity	≥99% — third-party COA verified, batch-specific documentation included
Status	Currently in Phase 3 clinical trials — not FDA approved

For research use only. Not for human consumption. This product is not approved for human use by the FDA or any regulatory body.

More Information

All products offered on this website are intended solely for laboratory research and development purposes. They are not approved for human or veterinary use.

Statements on this site have not been evaluated by the U.S. Food and Drug Administration (FDA). Products are not intended to diagnose, treat, cure, mitigate, or prevent any disease.

Products are manufactured in U.S.-based facilities operating under applicable cGMP standards. This website does not operate as a compounding pharmacy under Section 503A of the Federal Food, Drug, and Cosmetic Act.

A valid health screening is required prior to order fulfillment. After checkout, you will receive instructions to complete the required intake process. Orders will be processed once the screening has been completed and approved. Each completed screening remains valid for 12 months.